A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Janssen Pharmaceutical K.K.
ClinicalTrials.gov Identifier:
NCT00644787
First received: March 24, 2008
Last updated: June 6, 2013
Last verified: June 2013
  Purpose

The purpose of this study is to evaluate the efficacy and safety of fentanyl 1-day application (JNS020QD) transdermal patch (patch containing a drug that is put on the skin so the drug can enter the body through the skin) and to assess the non-inferiority of fentanyl 1-day application transdermal patch to fentanyl 3-day application (JNS005) transdermal patch in participants with cancer pain.


Condition Intervention Phase
Pain
Cancer
Drug: Fentanyl 1-day transdermal patch (Titration Phase)
Drug: Fentanyl 1-day transdermal patch (Double Blind Phase)
Drug: Fentanyl 3-day transdermal patch (Double Blind Phase)
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II/III Study of JNS020QD in Cancer Pain Patients - A Dose-Finding, Double-Blind Study of JNS020QD Compared With JNS005 in Patients Previously Untreated With Opioid Analgesics

Resource links provided by NLM:


Further study details as provided by Janssen Pharmaceutical K.K.:

Primary Outcome Measures:
  • Percentage of Participants Achieving Dose Titration Success [ Time Frame: Day 14 or early discontinuation (ED) ] [ Designated as safety issue: No ]
    Participants achieving dose titration success included all participants who had a mean Visual Analog Scale (VAS) score of less than or equal to 34 millimeter (mm) and received not more than 2 rescue doses during the last 3 days before the completion or discontinuation of dose titration phase. Pain Intensity VAS measured severity of pain on a 100 mm scale ranging from 0 mm (no pain) to 100 mm (severest pain conceivable) and rescue dose was defined as dose of a fast-acting oral morphine hydrochloride solution or morphine in water solution used in the case of breakthrough pain.

  • Change From Dose Titration Phase in the Mean Visual Analog Scale (VAS) Score at Double Blind Phase [ Time Frame: Dose Titration Phase (Day 12 to Day 14) and Double Blind Phase (Day 8 to Day 10) ] [ Designated as safety issue: No ]
    The mean VAS score for the last 3 days before the completion or discontinuation of Double Blind Phase was compared with that for the last 3 days before the completion or discontinuation of Dose Titration Phase and the change from Dose Titration Phase in the mean VAS Score at Double Blind Phase was reported. Pain Intensity VAS measured severity of pain on a 100 mm scale ranging from 0 mm (no pain) to 100 mm (severest pain conceivable).


Secondary Outcome Measures:
  • Number of Participants With Response Based on Participant's Global Assessment Scale in Titration Phase [ Time Frame: Day 1 pre-application (PA), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 11, Day 12, Day 13 and Day 14 or ED ] [ Designated as safety issue: No ]
    Participants were asked to assess their satisfaction with respect to the therapeutic efficacy (effectiveness) of the study drug to control pain on a 5-point scale ranging from 1 to 5, where 1 = extremely satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied and 5 = extremely dissatisfied.

  • Number of Participants With Response Based on Participant's Global Assessment Scale in Double Blind Phase [ Time Frame: Day 14-End of Titration Phase (ETP), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9 and Day 10 or ED ] [ Designated as safety issue: No ]
    Participants were asked to assess their satisfaction with respect to the therapeutic efficacy of the study drug to control pain on a 5-point scale ranging from 1 to 5, where 1 = extremely satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied and 5 = extremely dissatisfied.

  • Pain Intensity Visual Analog Scale (VAS) Score in Titration Phase [ Time Frame: Day 1 PA, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 11, Day 12, Day 13 and Day 14 or ED ] [ Designated as safety issue: No ]
    Participants were asked to assess their resting pain intensity (severity of pain) on a 100-mm VAS with the left edge (0 mm) defined as "no pain" and the right edge (100 mm) defined as "severest pain conceivable".

  • Pain Intensity Visual Analog Scale (VAS) Score in Double Blind Phase [ Time Frame: Day 14-End of Titration Phase (ETP), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9 and Day 10 or ED ] [ Designated as safety issue: No ]
    Participants were asked to assess their resting pain intensity (severity of pain) on a 100-mm VAS with the left edge (0 mm) defined as "no pain" and the right edge (100 mm) defined as "severest pain conceivable".

  • Percentage of Participants Achieving Pain Control in Double Blind Phase [ Time Frame: Day 10 or ED ] [ Designated as safety issue: No ]
    Pain control was assessed based on change in VAS and number of daily rescue doses during 3 days before completion of Double Blind Phase from 3 days before start of Double Blind Phase. For VAS score, difference of less than or equal to +15 mm and for rescue doses, difference of less than or equal to 1 was considered significant to achieve pain control. Pain Intensity VAS measured pain severity on a scale ranging from 0 mm (no pain) to 100 mm (severest pain conceivable) and rescue dose was defined as dose of fast-acting oral morphine formulation used in case of breakthrough pain.

  • Number of Participants With Pain Intensity Assessed by Categorical Scale for Pain in Titration Phase [ Time Frame: Day 1 PA, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 11, Day 12, Day 13 and Day 14 or ED ] [ Designated as safety issue: No ]
    Participants were asked to assess their resting pain intensity (severity of pain) on a 4-point categorical scale ranging from 0 to 3 where 0 = no pain, 1 = mild pain, 2 = moderate pain and 3 = severe pain.

  • Number of Participants With Pain Intensity Assessed by Categorical Scale for Pain in Double Blind Phase [ Time Frame: Day 14-End of Titration Phase (ETP), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9 and Day 10 or ED ] [ Designated as safety issue: No ]
    Participants were asked to assess their resting pain intensity (severity of pain) on a 4-point categorical scale ranging from 0 to 3 where 0 = no pain, 1 = mild pain, 2 = moderate pain and 3 = severe pain.

  • Number of Participants With Total Duration of Pain Per Day in Titration Phase [ Time Frame: Day 1 PA, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 11, Day 12, Day 13 and Day 14 or ED ] [ Designated as safety issue: No ]
    The participants assessed total painful time in 1 day on a 5-point scale ranging from 0 to 4 where 0 = less than (<) 4 hours, 1 = greater than or equal to (>=) 4 hours to less than 8 hours, 2 = greater than or equal to 8 hours to less than 12 hours, 3 = greater than or equal to 12 hours and 4 = 24 hours (all day).

  • Number of Participants With Total Duration of Pain Per Day in Double Blind Phase [ Time Frame: Day 14-End of Titration Phase (ETP), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9 and Day 10 or ED ] [ Designated as safety issue: No ]
    The participants assessed total painful time in 1 day on a 5-point scale ranging from 0 to 4 where 0 = less than (<) 4 hours, 1 = greater than or equal to (>=) 4 hours to less than 8 hours, 2 = greater than or equal to 8 hours to less than 12 hours, 3 = greater than or equal to 12 hours and 4 = 24 hours (all day).

  • Mean Number of Rescue Doses in Titration Phase [ Time Frame: Day 1 PA, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 11, Day 12, Day 13 and Day 14 or ED ] [ Designated as safety issue: No ]
    Rescue dose was defined as dose of a fast-acting oral morphine hydrochloride solution or morphine in water solution used in the case of breakthrough pain or lack of analgesic effect.

  • Mean Number of Rescue Doses in Double Blind Phase [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9 and Day 10 or ED ] [ Designated as safety issue: No ]
    Rescue dose was defined as dose of a fast-acting oral morphine hydrochloride solution or morphine in water solution used in the case of breakthrough pain or lack of analgesic effect.

  • Number of Participants With Response Based on Physician's Global Assessment Scale in Titration Phase [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
    The treating physician assessed the therapeutic efficacy of the study drug to control pain on a 2-point scale of effective and ineffective. Number of participants with effective and ineffective therapeutic efficacy with respect to the study drug were reported.

  • Number of Participants With Response Based on Physician's Global Assessment Scale in Double Blind Phase [ Time Frame: Day 10 ] [ Designated as safety issue: No ]
    The treating physician assessed the therapeutic efficacy of the study drug to control pain on a 2-point scale of effective and ineffective. Number of participants with effective and ineffective therapeutic efficacy with respect to the study drug were reported.


Enrollment: 156
Study Start Date: December 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fentanyl 1-day transdermal patch (Titration Phase)
Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14. Participants who met the predefined criteria at the end of Titration Phase enter the Double Blind Phase.
Drug: Fentanyl 1-day transdermal patch (Titration Phase)
Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
Other Name: JNS020QD
Experimental: Fentanyl 1-day transdermal patch (Double Blind Phase)
Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 1-day application transdermal patch and placebo matched to fentanyl 3-day application (JNS005) transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
Drug: Fentanyl 1-day transdermal patch (Double Blind Phase)
Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
Other Name: JNS020QD
Drug: Placebo
Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
Active Comparator: Fentanyl 3-day transdermal patch (Double Blind Phase)
Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 3-day application transdermal patch and placebo matched to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
Drug: Fentanyl 3-day transdermal patch (Double Blind Phase)
Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
Other Name: JNS005
Drug: Placebo
Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.

Detailed Description:

This is a multi-center (conducted in more than one center) study, consisting of two periods: Period 1 is open-label (all people know the identity of the intervention), non-comparative dose titration phase and Period 2 is double blind (neither physician nor participant knows the treatment that the participant receives), positive control (fentanyl 3-day application transdermal patch is used as control drug) phase. In Period 1, fentanyl 1-day application transdermal patch 12.5 microgram per hour (mcg/hr) will be applied to chest, abdomen, upper arm or thigh and will be maintained for 2 days to ensure the safety of participants. Dose escalation or reduction will be allowed based on participant's condition from Day 3 to Day 11 and thereafter dose will be maintained from Day 11 to Day 13 with a maximum application dose of 100 mcg/hr. The total duration of Period 1 is 14 days (a total of 13 applications; including the day of final patch removal). Participants who met the predefined criteria at the end of dose titration phase will enter the double blind phase. In double blind phase, participants will receive either fentanyl 1-day application transdermal patch and placebo matched to fentanyl 3-day application transdermal patch or fentanyl 3-day application transdermal patch and placebo matched to fentanyl 1-day application transdermal patch at the same dose as used at the completion of Period 1. The duration of Period 2 is 10 days. Efficacy will primarily be evaluated by percentage of participants achieving dose titration success and change in mean visual analog scale (VAS) score. Participants' safety will be monitored throughout the study.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants with cancer pain who were previously not treated with opioid analgesics (drug used to control pain)
  • Participants with a pain score of greater than or equal to 35 millimeter (mm) on a 100-mm visual analog scale (VAS)
  • Participants who are considered to have "insufficient response" to non-opioid analgesics and require treatment with opioid analgesics by the physician
  • Participants who have an established diagnosis of cancer and are notified of the disease
  • Participants who can be hospitalized during Period 1 (dose-titration period)

Exclusion Criteria:

  • Participants with impaired respiratory function due to chronic lung disease or others
  • Participants with asthma (breathing disorder in which there is wheezing and difficulty in breathing)
  • Participants with bradyarrhythmia (slow, irregular heartbeats)
  • Participants with following measurements indicative of hepatic or renal impairment during the pre-treatment observation period: Aspartate transaminase (AST) greater than 5 times the upper limit of reference range, Alanine transaminase (ALT) greater than 5 times the upper limit of reference range, serum creatinine greater than 3 times the upper limit of reference range
  • Participants with any cerebral damage, such as brain tumor, accompanied by increased intracranial pressure, disturbance of consciousness, coma, or respiratory disturbance
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00644787

Locations
Japan
Asahi, Japan
Asahikawa, Japan
Asahikawa N/A, Japan
Bunkyo, Japan
Chiba, Japan
Chikushino, Japan
Fukuoka, Japan
Fushimi, Japan
Higashi-Ibaraki, Japan
Higashi-Sonogi, Japan
Himeji, Japan
Hirosaki, Japan
Hiroshima, Japan
Hitachi, Japan
Hohfu, Japan
Ichinomiya, Japan
Ikeda, Japan
Iwakuni, Japan
Kawachi-Nagano, Japan
Kawasaki N/A, Japan
Kitakyushu, Japan
Kiyose N/A, Japan
Kobe, Japan
Kochi, Japan
Matsue, Japan
Matsuyama, Japan
Nishinomiya, Japan
Oita, Japan
Okayama, Japan
Osaka, Japan
Osaka N/A, Japan
Otake, Japan
Sakai, Japan
Sendai, Japan
Shigenobu N/A, Japan
Sunto, Japan
Tamaho N/A, Japan
Tokushima N/A, Japan
Tokyo, Japan
Toyohashi, Japan
Tsukuba, Japan
Utsunomiya, Japan
Wako, Japan
Yamaguchi, Japan
Yonago, Japan
Sponsors and Collaborators
Janssen Pharmaceutical K.K.
Investigators
Study Director: Janssen Pharmaceutical K.K., Japan Clinical Trial Janssen Pharmaceutical K.K.
  More Information

No publications provided

Responsible Party: Janssen Pharmaceutical K.K.
ClinicalTrials.gov Identifier: NCT00644787     History of Changes
Other Study ID Numbers: CR014899, JNS020QD-JPN-C02
Study First Received: March 24, 2008
Results First Received: April 1, 2013
Last Updated: June 6, 2013
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by Janssen Pharmaceutical K.K.:
Pain
Cancer
Fentanyl
JNS020QD
JNS005

Additional relevant MeSH terms:
Analgesics, Opioid
Fentanyl
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Adjuvants, Anesthesia
Narcotics
Anesthetics, Intravenous
Anesthetics, General
Anesthetics

ClinicalTrials.gov processed this record on April 17, 2014